Literature DB >> 19238552

The clinical management of chondrosarcoma.

Richard F Riedel1, Nicole Larrier, Leslie Dodd, David Kirsch, Salutario Martinez, Brian E Brigman.   

Abstract

OPINION STATEMENT: Chondrosarcomas (CHS) represent a heterogeneous group of disorders ranging from indolent, low-grade tumors to aggressive, high-grade forms. Surgical resection represents the primary and preferred treatment modality for individuals with localized disease. Radiation therapy is appropriate for the treatment of positive surgical margins or palliation of disease-related symptoms. The treatment of advanced, metastatic disease is particularly challenging given the recognition that conventional chemotherapy has proven to be largely ineffective. Systemic chemotherapy may be considered in variant forms such as mesenchymal or dedifferentiated chondrosarcomas but high-quality data supporting its use is limited. There is universal agreement, however, that novel treatment strategies are desperately needed. This review will highlight the need for a coordinated multidisciplinary approach to optimize the management and care of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19238552     DOI: 10.1007/s11864-009-0088-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  37 in total

Review 1.  Proton therapy for tumors of the skull base.

Authors:  J E Munzenrider; N J Liebsch
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

2.  Chondrosarcoma of bone: an oncological and functional follow-up study.

Authors:  J Bruns; M Elbracht; O Niggemeyer
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

3.  Proton radiation therapy for chordomas and chondrosarcomas of the skull base.

Authors:  E B Hug; L N Loredo; J D Slater; A DeVries; R I Grove; R A Schaefer; A E Rosenberg; J M Slater
Journal:  J Neurosurg       Date:  1999-09       Impact factor: 5.115

4.  Surgical treatment and outcome of conventional pelvic chondrosarcoma.

Authors:  D Donati; A El Ghoneimy; F Bertoni; C Di Bella; M Mercuri
Journal:  J Bone Joint Surg Br       Date:  2005-11

Review 5.  Chondrosarcoma of the pelvis. A review of sixty-four cases.

Authors:  M E Pring; K L Weber; K K Unni; F H Sim
Journal:  J Bone Joint Surg Am       Date:  2001-11       Impact factor: 5.284

Review 6.  Experience in charged particle irradiation of tumors of the skull base: 1977-1992.

Authors:  J R Castro; D E Linstadt; J P Bahary; P L Petti; I Daftari; J M Collier; P H Gutin; G Gauger; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

7.  Dedifferentiated chondrosarcoma: our clinico-pathological experience and dilemmas in 25 cases.

Authors:  Jelena Sopta; Aleksandar Dordević; Goran Tulić; Vesna Mijucić
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

8.  Does local recurrence impact survival in low-grade chondrosarcoma of the long bones?

Authors:  Joseph H Schwab; Doris Wenger; Krishnan Unni; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2007-09       Impact factor: 4.176

9.  Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones.

Authors: 
Journal:  J Bone Joint Surg Am       Date:  2007-10       Impact factor: 5.284

10.  Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report.

Authors:  Timothy A Damron; William G Ward; Andrew Stewart
Journal:  Clin Orthop Relat Res       Date:  2007-06       Impact factor: 4.176

View more
  47 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.

Authors:  Caroline Peyrode; Valérie Weber; Emmanuelle David; Aurélien Vidal; Philippe Auzeloux; Yves Communal; Marie Mélanie Dauplat; Sophie Besse; François Gouin; Dominique Heymann; Jean Michel Chezal; François Rédini; Elisabeth Miot-Noirault
Journal:  Invest New Drugs       Date:  2011-04-16       Impact factor: 3.850

Review 3.  Imaging pediatric bone sarcomas.

Authors:  Sue C Kaste
Journal:  Radiol Clin North Am       Date:  2011-06-16       Impact factor: 2.303

Review 4.  Cartilage diseases.

Authors:  Yamini Krishnan; Alan J Grodzinsky
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

5.  FOXA1 transcriptionally up-regulates cyclin B1 expression to enhance chondrosarcoma progression.

Authors:  Zong-Shin Lin; Chiao-Chen Chung; Yu-Chia Liu; Tsung-Ming Chen; Yung-Luen Yu; Shao-Chun Wang; Ya-Huey Chen
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

6.  Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Authors:  Kehan Xu; Bo Li; Quan Huang; Dongjie Jiang; Haitao Sun; Nanzhe Zhong; Wei Wan; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-05-04       Impact factor: 3.134

7.  Chondrosarcoma apoplexy in thoracic spine.

Authors:  Sang Woo Kim; Min Su Kim; Young Jin Jung
Journal:  J Korean Neurosurg Soc       Date:  2013-01-31

8.  Radiation therapy is associated with fewer recurrences in mesenchymal chondrosarcoma.

Authors:  Satoshi Kawaguchi; Israel Weiss; Patrick P Lin; Winston W Huh; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

9.  Chondrosarcoma in the mental foramen region of the mandible: A case report.

Authors:  Hongwei Liu; Xiuhong Chen; Teng Wan; Ren Li
Journal:  Oncol Lett       Date:  2016-07-14       Impact factor: 2.967

10.  ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.